How to access Voxzogo from the UAE — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A UAE family of a child with achondroplasia may receive a prescription for Voxzogo (vosoritide) from their treating paediatric endocrinologist or geneticist. Voxzogo is FDA-approved, manufactured by BioMarin, and is a C-type natriuretic peptide analogue indicated to improve linear growth in children with achondroplasia whose epiphyses are not closed. Achondroplasia is caused by a pathogenic variant in the FGFR3 gene. In the UAE, Voxzogo is not locally registered for routine dispensing, which is why your paediatric specialist is likely guiding you toward the Ministry of Health and Prevention (MoHAP) named-patient import pathway.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Voxzogo is a daily subcutaneous injection administered at home by a caregiver after training. Eligibility is based on genetic confirmation of achondroplasia (FGFR3 pathogenic variant) and open epiphyses confirmed on imaging. Treatment requires a paediatric endocrinologist or geneticist for baseline assessment, height/growth-velocity tracking, and ongoing blood-pressure monitoring (Voxzogo can cause transient blood-pressure decreases after injection). Your physician sets the schedule and coordinates caregiver injection training. Dosing is weight-based and continues until epiphyseal closure.
Is Voxzogo legally importable into the UAE?
Yes — through the MoHAP named-patient import framework. Parallel authority operates in Abu Dhabi through the Department of Health (DoH) and in Dubai through the Dubai Health Authority (DHA), depending on where the prescribing facility is located.
The named-patient mechanism allows a UAE-licensed physician to import a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally registered alternative is available, (c) the physician takes clinical responsibility, and (d) chain of custody is documented end to end. For achondroplasia in the UAE, there is no locally registered disease-modifying alternative, making the clinical rationale direct.
How the pathway works, step by step
- Consultation with your paediatric endocrinologist or geneticist. Genetic confirmation of achondroplasia, baseline height/weight, growth-velocity assessment, epiphyseal status on imaging, and cardiovascular baseline documented.
- Caregiver injection training. Your care team schedules training in subcutaneous injection technique and blood-pressure observation post-injection.
- MoHAP named-patient application. Your physician or the hospital pharmacy files the application with clinical rationale, genetic report, patient reference, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Voxzogo from BioMarin's authorised distribution channel.
- Cold-chain shipment. Voxzogo ships under cold-chain with chain-of-custody documentation.
- Arrival and dispensing. The hospital pharmacy releases the supply to the family; the paediatric team schedules monthly clinic reviews to track growth velocity and blood pressure.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming achondroplasia diagnosis, FGFR3 genetic report, baseline auxology, open-epiphysis confirmation, and Voxzogo as the indicated treatment
- Verification of their UAE medical licence
- A copy of the FGFR3 genetic report and growth-plate imaging
- Patient identifier (anonymised reference where possible)
- An administration and monitoring plan including caregiver training, blood-pressure surveillance, and growth-velocity tracking
Reserve Meds provides a physician documentation kit that bundles the templates MoHAP (or DoH/DHA) reviewers expect to see for rare-paediatric-endocrinology named-patient imports, including caregiver-administration training documentation.
Costs and timing
Voxzogo is weight-dependent in dosing, so annual cost scales with the child's body weight. Indicative 2026 US cash-pay annual cost sits in a broad range of roughly USD 320,000–450,000 depending on weight. International cold-chain logistics, MoHAP documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 14–28 days from the moment a complete MoHAP application is submitted. Refills ship on a rolling basis against the monthly dispensing schedule.
Reserve Meds is in pre-launch. Fulfilment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
A culturally-aware note: the UAE's paediatric rare-disease community includes both Emirati and expatriate families, with care often coordinated across multiple cities — Abu Dhabi, Dubai, Sharjah, and sometimes home-country follow-up for expatriate families. Daily home injections ask commitment from the designated caregiver; our concierge coordination plans refill logistics around school terms, Ramadan, and family travel, with a single case lead as continuity contact across the family's chosen care locations.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Voxzogo specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for MoHAP (or DoH/DHA) review.
- Logistics. Cold-chain shipment coordination to the prescribing hospital pharmacy with refill cadence planning.
- Concierge case lead. A named point of contact for the family, managing long-term refill logistics and weight-based dose adjustments as the child grows.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating paediatric specialist. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP (or DoH/DHA) named-patient framework with appropriate documentation. See our trust and compliance page.
Does Voxzogo cure achondroplasia? No. Voxzogo is a disease-modifying therapy shown in pivotal studies to improve annualised growth velocity. Your paediatric team will discuss realistic outcome expectations and the anticipated duration of therapy until epiphyseal closure.
Can we travel with Voxzogo? Yes, with planning. Cold-chain handling during travel is important; our concierge team provides travel-logistics support and documentation for cross-border movement of the medication.
What monitoring is required? Blood pressure observation post-injection in early dosing, regular growth-velocity assessment, and periodic imaging to monitor epiphyseal status. Your paediatric team sets the cadence.
Will insurance cover this? Cash-pay is the default. Some UAE insurers consider rare-paediatric-disease imports case by case; we supply documentation for submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Voxzogo coordination in the UAE.
Add me to the Voxzogo waitlistComposite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.